3/23/24

RUNX1 Attenuates Toll-Like Receptor and Type I Interferon Signaling in Neutrophils

Dr. Nancy Speck shares her research findings around the regulatory role of RUNX1 in inflammation, specifically how loss of RUNX1 results in epigenetic reprogramming that reduces control of TLR4 and type I IFN signaling pathways, leading to an increase in retrotransposons activity.
Previous

RRP Patient Meeting 2023: Scientific Conference Outcomes and Updates

Next

The RUNX1 Research Program - 5 Years of Success